Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mEHT and TCM vs IPCI in Peritoneal Carcinomatosis With Malignant Ascites
NCT02638051Phase 2Completed
- Sponsor
- Galenic Research Institute
- Start
- Jan 2014
- Primary completion
- Dec 2014
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in peritoneal carcinomatosis (PC) and malignant ascites (2 arms), sponsored by Galenic Research Institute. Primary endpoint: Objective Response Rate at 8 weeks. Started Jan 2014; status: completed.
02
Conditions
peritoneal carcinomatosis (PC)malignant ascites
Beyond the preview
Go deeper on NCT02638051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638051.